Home > Protocol Summaries: Compounds > SB513026(Primary) Protocol Summaries: SB513026(Primary) GSKStudy ID Phase Title Status 100409 phase 2 A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects Completed 513026/004 phase 2 An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population. Completed
